FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308395735> ?p ?o ?g. }

• W4308395735 abstract "<h3>Background</h3> Adoptive cell therapy (ACT) with <i>ex-vivo</i> expanded tumor infiltrating lymphocytes (TILs) has shown remarkable results in patients with metastatic melanoma (MM).^{1, 2} There is a crucial need for noninvasive biomarkers for screening patients which could improve the selection of patients responsive to therapy. Most studies have until now investigated phenotype, numbers, and persistence of infused TILs, while the role of peripheral immune cell in this process is still poorly understood. Here, we sought to elucidate potential peripheral immune signatures before and early on-treatment to predict patients with clinical outcome of ACT-TIL therapy, as well as characterize its impact on circulating immune cells. <h3>Methods</h3> Here we retrospectively analyzed peripheral blood mononuclear cells (PBMCs) and serum on-treatment changes from 45 patients with MM treated at our cancer center in one of three clinical trials: Study I (NCT00937625),³ Study II (NCT02379195),⁴ and Study III ( NCT02354690).⁵ Three multicolor flow cytometry panels were developed, two focused on T cells and one designed to measure all major mononuclear subsets and their characteristics. Data were evaluated by algorithm-based clustering and manual gate-setting of major immune cell subsets. Multiplex Luminex and ELISA was used to analyze serum samples to further reveal specific cytokine profiles of responsiveness to TIL therapy. <h3>Results</h3> Higher frequency of CD8⁺effector memory (EM) T cells was the only subset characterizing a peripheral immune signature of responsiveness pre-TIL. However, post-TIL therapy multiple immune subsets were associated with clinical outcome. Non-responders were characterized by mobilization of monocytic and NK subsets at the expense of CD4⁺ T cells and several subsets of dendritic cells (DCs). While major pro-inflammatory cytokines, IL-6 and IL-8, decreased post-TIL in responding patients they persisted in non-responding patients. In contrast, responders post-TIL therapy was characterized by higher frequency of both cDC2s and pDCs, CD4⁺ T cells and a subpopulation of CD4⁺ EM T cells expressing CD28, CD29, CD95, and PD-1. <h3>Conclusions</h3> While TIL therapy encompasses adoptive transfer of <i>ex-vivo</i> expanded preexisting TILs such therapy seems to modify both lymphoid and myeloid cell populations in peripheral blood. This indicates that early on-treatment peripheral immune signature of responsiveness to TIL therapy is characterized by higher frequency of CD4⁺ T cells and subsets of DCs, and a decrease in inflammatory cells and their mediators. <h3>Trial Registration</h3> NCT00937625, NCT02379195, NCT02354690 <h3>References</h3> Rosenberg, Steven A, <i>et al</i>. Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer ImmunotherapyComplete Regressions in Melanoma. <i>Clinical cancer research</i>. 2011;<b>17</b>(13):4550-4557. Dafni, U, <i>et al</i>. Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis. <i>Annals of Oncology</i>. 2019;<b>30</b>(12):1902-1913. Andersen, Rikke, <i>et al</i>. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen TIL Therapy for Melanoma Patients with Attenuated IL2 Dose. <i>Clinical cancer research</i>. 2016;<b>22</b>(15):3734-3745. Andersen R, <i>et al</i>. T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression. <i>Annals of Oncology</i>. 2018;<b>29</b>(7):1575-1581. Borch, Troels Holz, <i>et al</i>. Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma. <i>Journal for ImmunoTherapy of Cancer.</i> 2021;<b>9</b>(7). <h3>Ethics Approval</h3> The Ethical Committee of the Capital region of Denmark, the Danish Data Protection Agency and the Danish Medical Agencies approved Study I (NCT00937625: EudraCT no. 2008-008141-20), Study II (NCT02379195: EudraCT no. 2014-001420-29), and Study III ( NCT02354690: EudraCT no. 2014-001419-38)." @default.
• W4308395735 created "2022-11-11" @default.
• W4308395735 creator A5004642904 @default.
• W4308395735 creator A5035410537 @default.
• W4308395735 creator A5071648834 @default.
• W4308395735 creator A5073488854 @default.
• W4308395735 creator A5073711705 @default.
• W4308395735 date "2022-11-01" @default.
• W4308395735 modified "2023-09-25" @default.
• W4308395735 title "612 Peripheral immune signature of responsiveness to adoptive cell therapy with ex vivo expanded TILs using high dimensional single cell analysis" @default.
• W4308395735 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0612" @default.
• W4308395735 hasPublicationYear "2022" @default.
• W4308395735 type Work @default.
• W4308395735 citedByCount "0" @default.
• W4308395735 crossrefType "proceedings-article" @default.
• W4308395735 hasAuthorship W4308395735A5004642904 @default.
• W4308395735 hasAuthorship W4308395735A5035410537 @default.
• W4308395735 hasAuthorship W4308395735A5071648834 @default.
• W4308395735 hasAuthorship W4308395735A5073488854 @default.
• W4308395735 hasAuthorship W4308395735A5073711705 @default.
• W4308395735 hasBestOaLocation W43083957351 @default.
• W4308395735 hasConcept C10882517 @default.
• W4308395735 hasConcept C137061746 @default.
• W4308395735 hasConcept C143998085 @default.
• W4308395735 hasConcept C1491633281 @default.
• W4308395735 hasConcept C150903083 @default.
• W4308395735 hasConcept C167672396 @default.
• W4308395735 hasConcept C202751555 @default.
• W4308395735 hasConcept C203014093 @default.
• W4308395735 hasConcept C207001950 @default.
• W4308395735 hasConcept C26291073 @default.
• W4308395735 hasConcept C2776090121 @default.
• W4308395735 hasConcept C2777701055 @default.
• W4308395735 hasConcept C54355233 @default.
• W4308395735 hasConcept C553184892 @default.
• W4308395735 hasConcept C55493867 @default.
• W4308395735 hasConcept C71924100 @default.
• W4308395735 hasConcept C86803240 @default.
• W4308395735 hasConcept C8891405 @default.
• W4308395735 hasConceptScore W4308395735C10882517 @default.
• W4308395735 hasConceptScore W4308395735C137061746 @default.
• W4308395735 hasConceptScore W4308395735C143998085 @default.
• W4308395735 hasConceptScore W4308395735C1491633281 @default.
• W4308395735 hasConceptScore W4308395735C150903083 @default.
• W4308395735 hasConceptScore W4308395735C167672396 @default.
• W4308395735 hasConceptScore W4308395735C202751555 @default.
• W4308395735 hasConceptScore W4308395735C203014093 @default.
• W4308395735 hasConceptScore W4308395735C207001950 @default.
• W4308395735 hasConceptScore W4308395735C26291073 @default.
• W4308395735 hasConceptScore W4308395735C2776090121 @default.
• W4308395735 hasConceptScore W4308395735C2777701055 @default.
• W4308395735 hasConceptScore W4308395735C54355233 @default.
• W4308395735 hasConceptScore W4308395735C553184892 @default.
• W4308395735 hasConceptScore W4308395735C55493867 @default.
• W4308395735 hasConceptScore W4308395735C71924100 @default.
• W4308395735 hasConceptScore W4308395735C86803240 @default.
• W4308395735 hasConceptScore W4308395735C8891405 @default.
• W4308395735 hasLocation W43083957351 @default.
• W4308395735 hasOpenAccess W4308395735 @default.
• W4308395735 hasPrimaryLocation W43083957351 @default.
• W4308395735 hasRelatedWork W1983363132 @default.
• W4308395735 hasRelatedWork W1989723678 @default.
• W4308395735 hasRelatedWork W2380934607 @default.
• W4308395735 hasRelatedWork W2393477958 @default.
• W4308395735 hasRelatedWork W2400958657 @default.
• W4308395735 hasRelatedWork W2953447703 @default.
• W4308395735 hasRelatedWork W2972882834 @default.
• W4308395735 hasRelatedWork W3174314443 @default.
• W4308395735 hasRelatedWork W4319063722 @default.
• W4308395735 hasRelatedWork W4328048881 @default.
• W4308395735 isParatext "false" @default.
• W4308395735 isRetracted "false" @default.
• W4308395735 workType "article" @default.